Harrow (HROW) is drawing fresh attention after recent trading left the stock down about 24% over the past month and about 39% over the past 3 months, bringing increased focus to its eyecare business.

That recent slide sits in contrast to Harrow’s longer record, with the share price down sharply over the past 3 months but the 1-year total shareholder return still positive and the 5-year total shareholder return above 200%, suggesting sentiment has cooled after a strong multi year run.

If the recent volatility in Harrow has you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 30 healthcare AI stocks

So with Harrow’s share price pulling back even as its 1 year and 5 year returns remain in the green, is the stock now trading below what the business could be worth, or is the market already pricing in future growth?

Most Popular Narrative: 54.9% Undervalued

Harrow closed at $30.86, while the most widely followed narrative anchors on a fair value of $68.38, framing the recent pullback as a steep discount.

The rapidly growing demand for Harrow's portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool, supporting sustainable long-term revenue growth.

Curious what has to happen for that price gap to close? The narrative leans on brisk revenue expansion, sharply higher margins and a future earnings multiple that assumes those targets are met.

Result: Fair Value of $68.38 (UNDERVALUED)

However, this hinges on Harrow executing cleanly. Any slowdown in VEVYE or IHEEZO uptake or pricing pressure could quickly challenge the current undervalued narrative.

Next Steps

If this mix of optimism and concern feels familiar, now is the time to look through the details yourself and decide what stands out most, starting with 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If Harrow has your attention, do not stop there, use screeners to uncover other opportunities so you are not relying on a single stock story.

• Target higher potential upside by scanning screener containing 21 high quality undiscovered gems that combine quality fundamentals with under-the-radar profiles.
• Strengthen portfolio resilience by reviewing 67 resilient stocks with low risk scores that score well on financial stability and risk metrics.
• Balance growth and defense by checking 10 dividend fortresses offering higher yields while still anchored by underlying fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.